RVL Pharmaceuticals plc
RVL Pharmaceuticals plc
Your view on RVLPQ
Overview
What the company does, where it operates, and who runs it.
About RVL Pharmaceuticals plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Brian A. Markison
- Headquarters
- 400 Crossing Boulevard, Bridgewater, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Brian A. Markison
- Headquarters
- 400 Crossing Boulevard, Bridgewater, NJ, US
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.
It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for RVL Pharmaceuticals plc, and the rating behind it. RVLPQ last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for RVL Pharmaceuticals plc. Starting points for RVL Pharmaceuticals plc: EPS -$0.58, beta -31.16 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for RVL Pharmaceuticals plc. RVL Pharmaceuticals plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for RVL Pharmaceuticals plc. Trailing twelve-month EPS for RVL Pharmaceuticals plc stands at -$0.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for RVL Pharmaceuticals plc. RVL Pharmaceuticals plc has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
RVL Pharmaceuticals plc valued side by side against its closest peers. RVL Pharmaceuticals plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold RVL Pharmaceuticals plc, and how their positions are changing. At a $1,114 market value, institutional positions materially move RVL Pharmaceuticals plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by RVL Pharmaceuticals plc executives and directors. Shares of RVL Pharmaceuticals plc have traded between $0.0000 and $0.0005 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming RVL Pharmaceuticals plc. RVL Pharmaceuticals plc is a $1,114 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming RVL Pharmaceuticals plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for RVL Pharmaceuticals plc. Coverage tracks RVL Pharmaceuticals plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.